Skip to main content

Table 4 Cohort study: preadmission statin use and prognosis within 30 days following hospitalization for pneumonia in Denmark (1997-2009)

From: The impact of statin use on pneumonia risk and outcome: a combined population-based case-control and cohort study

Statin use Pneumonia patients
(n = 70,953)
Number of deaths 30-day mortality, percentage Crude HR
(95% CI)
Adjusteda HR
(95% CI)
Never 61,827 9,282 15.1 1.00 (reference) 1.00 (reference)
Former (>125 days) 1,903 272 14.3 0.95 (0.84-1.07) 0.91 (0.80-1.03)
Current (≤125 days) 7,223 813 11.3 0.74 (0.69-0.79) 0.73 (0.67-0.79)
Current (≤125 days) supplementary adjusted model for 2001-2009 6,883 788 11.4 0.77 (0.71-0.83) 0.76 (0.70-0.83)
  1. aAdjusted for age, sex, calendar period, marital status, urbanization of place of residence, any recent surgical procedure, 20 different comorbidities, alcoholism-related conditions, and 19 different preadmission medications. The supplementary model for 2001-2009 is also adjusted for receipt of current year's influenza vaccine, dementia, social medicine-related consultations, application for reimbursement for chronic and terminal illness, conversational therapy, and preventive consultations and services. CI, confidence interval; HR, hazard ratio.